IRF3 and systemic lupus erythematosus: In addition, since we found 8-HD activity in regulation of IRF-3 signaling pathway with general in vitro model of inflammation, the related confirmation of its activity upon IRF-3-associated inflammatory disease condition such as atopic dermatitis, chronic hepatitis, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, inflammatory bowel disease, chronic obstructive pulmonary disease, and type II diabetes must be included in the future studies, including using in vivo model.